Every AXLRx Dravet Syndrome report, across 9 report types and 3 markets. Each is scoped to your asset and verified to a live source.
US incidence 1 in 15,700, de novo SCN1A genetics, and one of the highest SUDEP rates documented in epilepsy.
Fintepla's list price runs roughly 3x Epidiolex, and payer scrutiny turns on high WAC against a small, severe paediatric population.
Fenfluramine leads on efficacy, cannabidiol anchors the lower-cost branded option, and stiripentol holds the adjunct niche.
GCC Dravet prescribing runs opposite the US/EU hierarchy: cannabidiol is de-facto inaccessible under narcotics law, so stiripentol, not cannabidiol, is the de-facto specialist standard of care.
The 1,400–2,000-patient refractory Dravet cohort is the opening. REMS-free cardiac safety and a 45%-Medicaid access plan decide who reaches it.
Cannabidiol and fenfluramine anchor the NHS-commissioned NICE algorithm; stiripentol still holds a backbone role. New entrants must beat an entrenched three-drug sequence, not just show efficacy.
Why NICE recommended both Dravet therapies through standard Technology Appraisal rather than the ultra-rare HSS route, what the Fintepla Cardiac Monitoring Scheme costs the NHS, and why the UK treatment algorithm is now closed to new entrants without a significant clinical edge.
6,000-8,000 US Dravet patients, roughly three-quarters SCN1A-confirmed, and 35-40% still inadequately controlled on cannabidiol plus fenfluramine, the population any new agent must actually reach.
2,000-2,500 UK Dravet patients, of whom 400-500 are SCN1A-molecularly-confirmed in genetic registries, and 600-900 still inadequately controlled on cannabidiol plus fenfluramine.
600-800 estimated GCC Dravet patients, fewer than 200 SCN1A-molecularly-confirmed, and a 200-400 near-term addressable cohort within that confirmed subset.
SCN1A molecular confirmation gap, the cannabidiol regulatory restriction, and the stiripentol-backbone standard of care across GCC paediatric neurology.
The UK's NICE-commissioned Dravet treatment algorithm manages an estimated 2,000-2,500 patients on cannabidiol and fenfluramine, but the NHS genetic testing registry logs only 400-500 molecularly SCN1A-confirmed cases — a registry-scope gap, not a population contradiction.
GCC Dravet prevalence is estimated at 600-800 patients from epidemiology, but fewer than 200 are molecularly SCN1A-confirmed, and the 200-400 figure used in launch planning is a distinct near-term actionable tier, not a fourth competing total.
Six NHS centres, Great Ormond Street, Bristol, Alder Hey, Birmingham Children's, Leeds, and Newcastle, concentrate the UK's refractory Dravet syndrome cohort, and the British Paediatric Neurology Association's Dravet working group shapes NICE evidence review 18-24 months ahead of submission. That institutional network is what this workbook sizes first, not a roster of named physicians.
Why the most effective Dravet agent is the least accessible in the GCC — cannabidiol's Schedule-1-equivalent narcotics classification caps exceptional-import approval at 35-40%.
Both existing Dravet therapies cleared NICE's standard Technology Appraisal, not the ultra-rare Highly Specialised Technology route. A new entrant's WAC, PAS, and stakeholder-engagement calendar all need to be built against that lower cost-effectiveness bar, with soticlestat's 2026-27 appraisal setting the clock.
The 600-900 UK Dravet patients still uncontrolled on CBD plus fenfluramine, the cardiac-monitoring burden a REMS-free agent could remove, and the soticlestat clock competing for the same refractory population.
NHS GMS free SCN1A testing, a NICE-defined CBD-then-fenfluramine algorithm, and 25 paediatric epilepsy HSS centres running the most treatment-advanced Dravet pathway in Europe.
The binding constraint for a new Dravet agent in GCC is regulatory classification, not efficacy — any agent must clear the SFDA Controlled Drug Board as non-controlled, because CBD-class compounds are permanently excluded.
Fintepla's weight-based list price runs roughly 3x Epidiolex, and payers work that gap through step-edit design layered on Part D pharmacy-benefit routing. No generic cannabidiol reaches the US market before the late 2030s.
Both NHS-commissioned Dravet therapies cleared NICE's standard £20,000-30,000/QALY bar, not the ultra-rare HSS threshold, so a new entrant is held to the same cost-effectiveness bar the incumbents already cleared. Total NHS Dravet spend still runs a modest £9-16M.
GCC Dravet pricing is an import-cost economics problem, not a rebate negotiation: cannabidiol's Schedule-1-equivalent narcotics classification adds USD 10-15K in compassionate-programme cost plus SAR 5-8K in import logistics, while stiripentol's non-narcotic status keeps it at SAR 30-50K through standard hospital import.
US Dravet syndrome incidence of 1 in 15,700 births is consistent with the Dravet Syndrome Foundation's 6,000-8,000 prevalence estimate, but only 35-40% of that population, 1,400-2,000 patients, remains inadequately controlled on today's two branded agents.
A five-institution Saudi pediatric neurology consortium spanning Riyadh, Jeddah, and Dammam tracked 44 Dravet syndrome patients on stiripentol combination therapy. That kind of coordinated, cross-city publication is exactly the institutional signal this workbook sizes before any individual name enters it.
AXLRx publishes Disease Landscape, Payer & HTA, Competitive Intelligence, Launch Readiness, Patient Flow Model, Market Sizing Model, KOL Mapping, HTA Strategy Model, and Pricing Strategy Model for Dravet Syndrome. Each report is scoped to your asset, verified to a live source, and delivered in 72 hours.
Current Dravet Syndrome coverage spans United States, GCC (Gulf), and United Kingdom. Additional markets can be commissioned against the same evidence standard.
Every figure is cited to a live source at the point of writing and re-checked in an independent audit pass. The latest Dravet Syndrome reports were updated July 2026.